Primary care physician involvement increases likelihood of cancer screening in people with cystic fibrosis: A population-based study from Ontario, Canada [0.03%]
加拿大安大略省基于人口的研究：初级保健医生的参与提高了囊性纤维化患者的癌症筛查率
Anne L Stephenson,Isobel Sharpe,Jenna Sykes et al.
Anne L Stephenson et al.
Background: People with cystic fibrosis (pwCF) are living longer and with an increased risk of malignancies, preventative cancer screening is crucial. The objectives of this study were to determine cancer screening rates ...
The role of islet CFTR in the development of cystic fibrosis-related diabetes: A semi-systematic review [0.03%]
囊性纤维化跨膜转导调节因子在糖尿病发病中的作用：系统综述
Matilda Engström,Efraim Westholm,Anna Wendt et al.
Matilda Engström et al.
Background: Cystic fibrosis related diabetes (CFRD) is the most common comorbidity of cystic fibrosis (CF) still, its pathogenesis is poorly understood. Recent studies have suggested that although pancreatic insufficiency...
Remote monitoring of cystic fibrosis lung disease in children and young adults [0.03%]
儿童和年轻人远程监测囊性纤维化肺病
Marcus Svedberg,Jens Michelsen,Emma Roberts et al.
Marcus Svedberg et al.
Aim: Cystic fibrosis (CF) care increasingly demands flexible and personalised approaches, particularly with the growing role of telemedicine in disease management. This study aimed to evaluate the use of home-based spirom...
Resolution of portal hypertension in a patient with cystic fibrosis after treatment with CFTR modulator: A case report [0.03%]
应用CFTR调制剂治疗囊性纤维化患者的门脉高压缓解——一例报告
Erica Loon,Joanne Billings,Nicholas Lim
Erica Loon
Portal hypertension (pH) secondary to cystic fibrosis liver disease (CFLD) is the fourth most common cause for mortality (after respiratory/cardiorespiratory, transplant-related, and cancer-related) in adults with cystic fibrosis (CF) and m...
Cystic Fibrosis-related neurodegenerative disease associated with tauopathy and cognitive decline in aged CF mice [0.03%]
囊性纤维化相关神经退行性疾病与tau病变和年老囊性纤维化小鼠的认知下降有关
Danica F Patton-Parfyonov,Xinming Wang,Sarah Barker et al.
Danica F Patton-Parfyonov et al.
Background: Highly effective modulator therapies (HEMT) are increasing the lifespan for many people with cystic fibrosis (pwCF), making it necessary to identify and understand CF specific age-related consequences. In this...
"Mind the gap"- will we ever see equal median predicted survival for males and females in cystic fibrosis? [0.03%]
“谨防差距”——在囊性纤维化患者中我们能否实现预测中位生存期的性别平等？
Jamie Duckers,Sarah L Clarke,Susan C Charman et al.
Jamie Duckers et al.
Trial design of bacteriophage therapy for nontuberculous mycobacteria pulmonary disease in cystic fibrosis: The POSTSTAMP study [0.03%]
CF患者非结核分枝杆菌肺病噬菌体治疗研究方案：POSTSTAMP试验设计
Jerry A Nick,Stacey L Martiniano,Valerie K Lovell et al.
Jerry A Nick et al.
Bacteriophages (phages) are viruses that selectively infect bacteria and have been utilized to treat Mycobacterium abscessus (Mab) with varying success. The POSTSTAMP study is an ongoing, multi-site phage therapy protocol for treatment-refr...
Catarina Pereira,Margarida D Amaral,Andre O Falcao
Catarina Pereira
Background: Cystic fibrosis (CF) is a disease triggered by more than 2,100 variants in a single gene encoding for the CF Transmembrane Conductance Regulator (CFTR) protein, which is expressed in epithelial cells, where it...
First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study [0.03%]
首个关于囊性纤维化胎儿治疗中使用CFTR调节剂的现实世界研究：MODUL-CF研究报道
Anne-Sophie Bonnel,Tiphaine Bihouée,Mélanie Ribault et al.
Anne-Sophie Bonnel et al.
Background: We aimed to build a cohort of Maternal-Cystic Fibrosis (CF) fetal dyads treated in utero with Variant Specific Therapy (VST), to assess the efficacy on Meconium Ileus (MI) and potential adverse effects of trea...
Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant [0.03%]
肺移植后同时使用他克莫司对Elexacaftor-tezacaftor-ivacaftor的药代动力学影响
J S Guimbellot,Ashritha Chalamalla,Elizabeth Baker et al.
J S Guimbellot et al.
Background: CFTR modulators in post-transplant people with cystic fibrosis (pwCF) are less frequently used due to uncertainty regarding effectiveness and interactions with immunosuppressive agents. Elexacaftor/tezacaftor/...